-
51.发明授权公开(公告)号：US11851481B2
公开(公告)日：2023-12-26
申请号：US17121553
申请日：2020-12-14
Applicant: Takeda Pharmaceutical Company Limited
Inventor： William H. Frey, II , Leah Ranae Bresin Hanson , Sharon Pokropinski , Francisco M. Rausa, III
IPC: C07K16/18 , A61K9/00 , C07K16/06 , A61K9/08 , A61K31/4172 , A61K31/401 , A61K31/198 , A61K39/00
CPC classification number: C07K16/18 , A61K9/0043 , A61K31/401 , A61K31/4172 , C07K16/06 , A61K9/08 , A61K31/198 , A61K2039/505 , A61K2039/543 , C07K2317/21 , C07K2317/55 , C07K2317/92
Abstract: The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.
-
52.发明公开公开(公告)号：US20230408528A1
公开(公告)日：2023-12-21
申请号：US18308813
申请日：2023-04-28
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Jiang Wu , Guodong Zhang , Daniel J. Sexton , Ryan Faucette , Gul M. Mustafa , Mark Szewc
CPC classification number: G01N33/6848 , G01N30/7233 , G01N30/88 , G01N33/6893 , G01N2030/027
Abstract: Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein. Such methods may comprise treating a biological sample with a protease to generate a plurality of digested peptides, and measuring one or more signature peptides, which are indicative of cleaved HMWK and/or full-length HMWK.
-
公开(公告)号：US20230399356A1
公开(公告)日：2023-12-14
申请号：US18336436
申请日：2023-06-16
Applicant: Takeda Pharmaceutical Company Limited
Inventor： He XU , Hong Myung LEE , Christopher ARENDT
IPC: C07H21/00 , A61K47/68 , A61P35/00 , A61K31/7084
CPC classification number: C07H21/00 , A61K47/6849 , A61P35/00 , A61K31/7084 , A61K47/6889
Abstract: The present disclosure provides antibody drug conjugates comprising STING modulators. Also provided are compositions comprising the antibody drug conjugates. The compounds and compositions are useful for stimulating an immune response in a subject in need thereof.
-
公开(公告)号：US20230395254A1
公开(公告)日：2023-12-07
申请号：US18006967
申请日：2021-07-27
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Jordan Brayanov , Cristina Menchero Almansa , Meena Subramanyam
IPC: G16H50/20 , G16H20/17 , A61B5/0205 , A61B5/00 , G16H40/67
CPC classification number: G16H50/20 , G16H20/17 , A61B5/02055 , A61B5/7475 , G16H40/67
Abstract: A method (500) for managing nausea includes receiving, from one or more monitoring devices (200), patient parameter data (212) of a patient (10). The patient parameter data is collected by the one or more monitoring devices. The method also includes determining, based on the patient parameter data of the patient, whether the patient is experiencing or about to experience an episode of nausea. When the patient is experiencing or about to experience an episode of nausea, the method also includes communicating one or more therapy signals (302, 304, 306, 308) to a receiver device (12, 21, 400) in communication with the computing device.
-
公开(公告)号：US20230381287A1
公开(公告)日：2023-11-30
申请号：US18231982
申请日：2023-08-09
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Yung Hee Park , Nancy Chen , Jun Hu , Muthuraman Meiyappan , Thomas Alllen Miller
IPC: A61K38/47 , A61K31/445 , A61K47/02 , A61K47/12 , A61K47/26
CPC classification number: A61K38/47 , A61K31/445 , A61K47/02 , A61K47/12 , A61K47/26 , A61K9/0019
Abstract: The invention provides a composition of glucocerebrosidase, such as velaglucerase alfa, and isofagomine, in a molar ratio of at least about 1:2.5. Also provided is a use of the composition for treatment of a disorder related to a dysfunction in a GCase pathway. The disorder could be a lysosomal storage disease, such as Gaucher disease, Fabry disease, Pompe disease, a mucopolysaccharidoses, or multiple system atrophy. The disorder could also be a neurodegenerative disorder, such as Parkinson disease, Alzheimer's disease, or Lewy body dementia. The composition can have 0.5 to 5.0 mg/kg of glucocerebrosidase and isofagomine in at least about a 3-fold molar excess to the glucocerebrosidase. The composition can be administered intravenously or subcutaneously.
-
Patent Agency Ranking
公开(公告)号：US20230381214A1
公开(公告)日：2023-11-30
申请号：US18200636
申请日：2023-05-23
Applicant: Takeda Pharmaceutical Company Limited
Inventor： John D. Peabody, III
IPC: A61K31/7056 , G09B19/00 , A61K45/06 , G01N33/94
CPC classification number: A61K31/7056 , G09B19/00 , A61K45/06 , G01N33/94 , G01N2430/00 , G01N2800/52
Abstract: The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.
-
公开(公告)号：US11815516B2
公开(公告)日：2023-11-14
申请号：US16333155
申请日：2017-09-15
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Daniel J. Sexton , Malini Viswanathan , Ryan Faucette , Tripti Gaur
CPC classification number: G01N33/6893 , A61K38/08 , C07K16/40 , G01N2333/47 , G01N2333/90 , G01N2333/99 , G01N2800/22 , G01N2800/52
Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
-
公开(公告)号：US20230348675A1
公开(公告)日：2023-11-02
申请号：US18310607
申请日：2023-05-02
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Venkata R. Garigapati , Tetsuo Hoshino , Amit Garle
CPC classification number: C08J3/075 , C08B37/0084 , C08J3/245 , C08L5/04 , C08L71/02 , C12N5/0018 , C08J2305/04 , C08L2203/02 , C12N5/0636
Abstract: The present application provides a semi-permeable hydrogel composition comprising an alginate matrix that is covalently crosslinked in its periphery to a multi-armed water soluble polymer, along with related methods and uses thereof.
-
公开(公告)号：US11783931B2
公开(公告)日：2023-10-10
申请号：US17119011
申请日：2020-12-11
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Gerald Spotts , Roman Pichler , Michael Nelson
IPC: G16H20/10 , G16C20/30 , G09C5/00 , G16H50/30 , G16H50/50 , G06N7/01 , G16H10/60 , H04L9/06 , G16B50/00 , G16B40/00 , G16C20/90
CPC classification number: G16H20/10 , G06N7/01 , G09C5/00 , G16C20/30 , G16H10/60 , G16H50/30 , G16H50/50 , H04L9/0637 , G16B40/00 , G16B50/00 , G16C20/90
Abstract: A drug monitoring tool comprises a data receiver and an interactive user interface. The data receiver is configured to receive a pharmacokinetic (PK) profile of a patient. The interactive user interface is configured to display, to the patient, a time-varying therapeutic plasma protein level of the patient and delineate a plurality of zones within the interactive user interface associated with the time-varying therapeutic plasma protein level. The plurality of zones includes a safe zone indicating to the patient that the time-varying therapeutic plasma protein level is within a first concentration range considered safe for physical activity and a danger zone indicating to the patient that the time-varying therapeutic plasma protein level is within a second concentration range and physical activity should be limited.
-
公开(公告)号：US20230295628A1
公开(公告)日：2023-09-21
申请号：US18163506
申请日：2023-02-02
Applicant: National University Corporation Tokyo Medical and Dental University , Takeda Pharmaceutical Company Limited
Inventor： Takanori Yokota , Tetsuya Nagata , Hideki Furukawa , Yasuo Nakagawa , Takatoshi Yogo , Ryosuke Tokunoh , Shigekazu Sasaki , Kosuke Hidaka , Tomohiro Seki , Kenichi Miyata , Akio Uchida
IPC: C12N15/113 , A61P25/00
CPC classification number: C12N15/113 , A61P25/00 , C12N2310/11 , C12N2310/341
Abstract: Developed and provided is: a nucleic acid agent that is efficiently delivered to the central nervous system, to which drug delivery is inhibited by the blood brain barrier mechanism, and that provides an antisense effect to a target transcription product at the delivery site; and a composition containing such a nucleic acid agent. Provided is a double-stranded nucleic acid complex consisting of a first nucleic acid strand and a second nucleic acid strand that are annealed to each other; wherein the first nucleic acid strand hybridizes with part of a target transcription product and has an antisense effect on the target transcription product; and wherein the second nucleic acid strand includes a base sequence complementary to the first nucleic acid strand and is conjugated to a phosphatidylethanolamine or an analog thereof.
-
-
-
-
-
-
-
-
-
Search Results
2080
records
(took 0.071 seconds)
